Skip to content

Omeros OMER Current ratio

Current ratio at other companies

Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
10.3×-1.3×
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
10.2×+7.0×
Immunome logo
ImmunomeIMNM
21.7×+11.2×
Vor Biopharma logo
Vor BiopharmaVOR
31.1×+27.3×
Annexon logo
AnnexonANNX
6.4×-1.6×
Arcus Biosciences logo
Arcus BiosciencesRCUS
-1.3×

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$775.86M+313%
P/S8.6×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×

Where this comes from

Calculated from Omeros’s reported figures.

Based on the most recent quarter.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's current ratio?
Omeros (OMER) reported current ratio of 3× in Q1 2026.
How has Omeros's current ratio changed year-over-year?
Omeros's current ratio increased by 162.5% year-over-year, from 1.2× to 3×.
What is the long-term trend for Omeros's current ratio?
Over 5 years (2020 to 2025), Omeros's current ratio has grown at a -7.7% compound annual growth rate (CAGR), from 4.1× to 2.8×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.